Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Apr;15(3):171-81.
doi: 10.1016/j.cardfail.2009.01.013.

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial

Brian E Jaski  1 , Mariell L Jessup, Donna M Mancini, Thomas P Cappola, Daniel F Pauly, Barry Greenberg, Kenneth Borow, Howard Dittrich, Krisztina M Zsebo, Roger J Hajjar; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators
Affiliations
Clinical Trial

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial

Brian E Jaski et al. J Card Fail. 2009 Apr.

Abstract

Background: SERCA2a deficiency is commonly seen in advanced heart failure (HF). This study is designed to investigate safety and biological effects of enzyme replacement using gene transfer in patients with advanced HF.

Methods and results: A total of 9 patients with advanced HF (New York Heart Association [NYHA] Class III/IV, ejection fraction [EF] < or = 30%, maximal oxygen uptake [VO2 max] <16 mL.kg.min, with maximal pharmacological and device therapy) received a single intracoronary infusion of AAV1/SERCA2a in the open-label portion of this ongoing study. Doses administered ranged from 1.4 x 10(11) to 3 x 10(12) DNase resistant particles per patient. We present 6- to 12-month follow-up data for these patients. AAV1/SERCA2a demonstrated an acceptable safety profile in this advanced HF population. Of the 9 patients treated, several demonstrated improvements from baseline to month 6 across a number of parameters important in HF, including symptomatic (NYHA and Minnesota Living with Heart Failure Questionnaire, 5 patients), functional (6-minute walk test and VO2 max, 4 patients), biomarker (NT-ProBNP, 2 patients), and LV function/remodeling (EF and end-systolic volume, 5 patients). Of note, 2 patients who failed to improve had preexisting anti-AAV1 neutralizing antibodies.

Conclusions: Quantitative evidence of biological activity across a number of parameters important for assessing HF status could be detected in several patients without preexisting neutralizing antibodies in this open-label study, although the number of patients in each cohort is too small to conduct statistical analyses. These findings support the initiation of the Phase 2 double-blind, placebo-controlled portion of this study.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Absolute change from baseline in ejection fraction over time.
Fig. 2
Fig. 2
Change from baseline in end systolic volume over time.
Fig. 3
Fig. 3
Change from baseline in New York Heart Association (NYHA) Class over time.
Fig. 4
Fig. 4
Change from baseline to month 6 in maximal oxygen uptake (VO2 max).
Fig. 5
Fig. 5
Change from baseline in 6-minute walk test over time.
Fig. 6
Fig. 6
Percent change from baseline in NT-Pro BNP over time.
Fig. 7
Fig. 7
Change from baseline in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) total score over time.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson T, Flegal K, et al. Heart Disease and stroke statistics–2009 update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation Epub. 2008 Dec 15;119:e21–181. - PubMed
    1. Cleland J, Swedberg K, Poole-Wilson P. Successes and failures of current treatment of heart failure. Lancet. 1998;352(Suppl 1):SI19–28. - PubMed
    1. Goldstein D, Oz M, Rose E. Implantable left ventricular assist devices. N Engl J Med. 1998;339:1522–33. - PubMed
    1. Hajjar R, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14:355–67. - PubMed
    1. del Monte F, Hajjar RJ, Harding SE. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ Res. 2001;88:E66–7. - PubMed

Publication types

Substances